Status:
COMPLETED
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
First Affiliated Hospital of the Army Medical University
Shengli Oilfield Hospital
Conditions:
Brachytherapy
Desmoid Tumor
Eligibility:
All Genders
13-75 years
Brief Summary
This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor. A multicenter retrospective study reviewed 38 recu...
Detailed Description
Desmoid tumor was characterized by a high potential of recurrence even following initial definitive treatment. There were considerable controversies regarding the management of recurrent desmoid tumor...
Eligibility Criteria
Inclusion
- 1\) recurrent desmoid tumor confirmed by pathologic or imaging diagnosis; 2) disease size ≥1 cm and ≤ 10 cm; 3) medically inoperable or individual refusal to resection; 4) Karnofsky performance status (KPS) ≥ 60; 5) adequate hematological reserves, hepatic function, renal function and heart function; 7) expected survival \> 3 months.
Exclusion
- 1\) unconfirmed mass; 2) tumor invading the skin or mucous membrane; 2) patients with severe bleeding tendency; 3) patients with active infectious disease, trauma and severe wounds; 4) patients with any mental disorder; 5) patients with other somatic comorbidities of clinical concern; 6) pregnancy and lactation
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT06195085
Start Date
July 1 2013
End Date
July 1 2023
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191